PRCS Praecis Pharmaceuticals (MM)

PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today announced that Kevin F. McLaughlin, President and Chief Executive Officer, and Richard W. Wagner, Ph.D., Executive Vice President, Discovery Research, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York on November 9, 2005. The PRAECIS presentation may be accessed live beginning November 9, at 12:20 p.m., EST, at http://www.praecis.com under "Investors." A copy of the presentation and a replay of the webcast will be available on the Company's website beginning at 3:00 p.m., EST, until midnight Friday, November 18. About PRAECIS PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies that either address unmet medical needs or offer improvements over existing therapies. PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for non-Hodgkin's lymphoma and solid tumors, as well as an innovative drug discovery technology, Direct Select(TM), which enables the generation and practical use of ultra-large libraries for the discovery of orally active compounds for drug development. PRAECIS has received approval to market Plenaxis(R) in both the United States and Germany.